Vantage Pharma, Biotech & Medtech Half-Year Review 2019

${downloadButtonText}

Mega-deals mask a significant decline in M&A activity for pharma and medtech 

The Vantage Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech in the first half of 2019.

Bristol-Myers Squibb’s $74bn pending purchase Celgene and Abbvie’s $63bn acquisition of Allergan have taken the headlines, positioning 2019 to be a record year for pharma M&A spend, while Verily’s $1bn round of funding in Q1 was the largest ever seen in the medtech.

However, these colossal deals are masking a substantial slowdown in the total number of M&A deals in both pharma and medtech, and pharma doubled down on this trend with a similar drop in licensing activity. Investors remain cautious due to potential US drug reforms and elsewhere the biotech boom appears to be over, except for a couple of isolated bubbles.

Key highlights

  • 2019 set to be a record year for pharma M&A spend, but mega-deals mask wider drop in deal numbers

  • Verily’s $1bn round of funding in Q1 was medtech’s largest ever, but the sector also experienced substantial declining deal numbers

  • Only 8 medtech companies went public during the first half of 2019, but collectively raised $1.3bn

  • Q2 biotech flotations raised $2bn, as investor enthusiasm attracts younger drug developers away from traditional M&A and partnerships

  • Uncertainty around potential US drug price reform continues to be a significant investor concern

EvaluatePharma World Preview 2015, Outlook to 2020

Worldwide Rx Sales Forecast to Grow 5% p.a. to 2020. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Key highlights

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

Download